President ????: What US Election Uncertainty Means For Biopharma

Worst case scenario is civil unrest that might disrupt clinical trials and manufacturing. Under a more moderate scenario, companies must delay business planning because the US policy environment remains cloudy.

Voting sticker with mask and flag

The biopharma industry faces extended planning challenges if the contest for US president between Joe Biden and incumbent Donald Trump remains unresolved and the future policy environment is unclear for much longer.

Ballots tabulated by the end of the day indicated the race was too close to call and results were not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Elections

More from Legislation